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Abstract Bladder cancer is a major public health prob-
lem. Currently available therapeutic options seem to be
unable to prevent bladder cancer recurrence and progres-
sion. To enable preclinical testing of new intravesical
therapeutic agents, a suitable bladder tumor model that
resembles human disease is highly desirable. The aim of
this topic paper was to discuss the problems associated with
current in vivo animal bladder tumor models, focusing on
the orthotopic syngeneic rat bladder tumor model. In the
second part of the paper the development of a potential new
orthotopic rat bladder tumor model is described.
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Introduction
Bladder cancer is one of the most common malignancies
with approximately 357,000 new cases (273,858 males and
82,699 females) worldwide in 2002 [1]. More than 90% of
the bladder cancers are urothelial cell carcinomas (UCC)
[2] and the majority (75–85%) presents initially as non-
muscle invasive bladder cancer (NMIBC) [3]. Of these
patients, about 70% presents with papillary lesions that are
non-invasive and limited to the mucosa (Ta), 20% with
lesions that invade the subepithelial connective tissue (T1)
and 10% with carcinoma in situ (CIS). Transurethral resec-
tion of the bladder tumor (TURBT), followed by adjuvant
intravesical instillations with chemotherapy and/or immu-
notherapy are considered standard treatment for NMIBC. In
general, the probabilities of recurrence and progression in
NMIBC at 5 years range from 31 to 78% and from less than
1–45% depending on grade and stage, respectively [4].
These rates illustrate the modest success of currently avail-
able treatments and underline the need for improved adju-
vant treatment.
Although in vitro models are useful for initial develop-
ment and evaluation of therapeutic agents and modalities,
adequate animal models are still essential in the preclinical
development of new eVective and safe therapies for many
human malignancies. It allows the investigation of aspects
that cannot be studied under clinical conditions such as
pharmacokinetics and toxicity. For bladder cancer in partic-
ular, much eVort has been devoted to the development of an
appropriate tumor model for the evaluation of new chemo-
therapeutic or immunotherapeutic agents, drug regiments,
or other anti-tumor modalities.
The ideal animal bladder tumor model that resembles
human disease both histologically and in behavior should
include the following characteristics [5]:
1. The tumor should grow intravesically (orthotopically),
such that the tumor can be directly exposed to intraves-
ical anti-tumor drugs in its natural environment.
2. The tumor should be of pure UCC origin, with diVerent
stages of disease progression (CIS, papillary and inva-
sive diseases) and, as for the human disease, the major-
ity of the tumors should be non-muscle invasive, but
not progressive.
3. The animal host should be immunocompetent and rea-
sonably large, so it can be treated by various anti-tumor
modalities such as immunotherapy with bacillus
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Calmette–Guérin (BCG), chemotherapy, and whole
bladder photodynamic therapy (PDT).
4. The tumor should be technically easy to develop within
a reasonable time period, and highly reproducible with
respect to its natural history.
In this topic paper, we discuss existing in vivo rat bladder
tumor models with their speciWc shortcomings. In the sec-
ond part of the paper, we describe the development of a
potential new orthotopic rat bladder tumor model.
Existing in vivo models
Rats and mice are the most common species used for in
vivo UCC models. Rodents have a lower urinary tract com-
parable to humans and neoplasms in the bladder are mor-
phologically very alike [6]. Bladder tumors in rodents can
be established subcutaneously (heterotopically) or in the
bladder (orthotopically) either by transplantation of tumor
cells or by chemical induction.
Although murine orthotopic models are available [e.g. 7,
8, 9], these models are limited by the size of the animal,
with a small urethral caliber, thin bladder wall and small
bladder capacity as a consequence. Catheterization of mice
to introduce tumor cells, intravesical therapeutics or for
example an ultrathin cystoscope is more diYcult than in
rats. A rat bladder is approximately 10 times larger than the
bladder of a mouse and the better developed muscular layer
allows better histological assessment of depth of invasion
and decreases the risk of perforation during bladder cathe-
terization [10]. Therefore, in important aspects the rat
model oVers signiWcant advantages over the murine model
and in this topic paper only the rat model is further dis-
cussed.
Subcutaneous models
In rodent heterotopic UCC models, the tumor is usually
located in the Xank or hind leg of the animal. To establish a
syngeneic subcutaneous model for immunological studies,
rodent UCC tumor fragments or cells are inoculated
through a small incision into the immunocompetent host of
the same strain from which the tumor was originally
derived [11, 12]. For a xenograft model human UCC frag-
ments or cells are used. Subcutaneous tumors can be evalu-
ated non-invasively by palpation or with the help of
imaging techniques. Treatment can be administered by
local injection or systemically.
Subcutaneous bladder tumor models have been widely
used because of the ease of assessing tumor growth kinetics
and because the orthotopic model is technically more diY-
cult (see below) [13, 14]. However, the microenvironment
at the implantation site of the host organ can inXuence the
natural history of tumor growth and the eYcacy of anti-pro-
liferative agents. In one study, for example [15], human
colon carcinoma cells were implanted into diVerent ana-
tomical locations (subcutaneous and cecum) of nude mice.
Tumor bearing mice were treated with doxorubicin and
subsequently evaluated for responses. The heterotopic sub-
cutaneous tumors showed an 80% inhibition of growth,
compared with 40% inhibition of the orthotopic intracecal
tumors. The environment of the orthotopic model resem-
bles that of naturally occurring tumors, so experimental
results in this model would be expected to have more rele-
vance than results in the subcutaneous model. In addition,
heterotopic grafts are unsuited to evaluate intravesical ther-
apies and orthotopic models are thus to be preferred.
Orthotopic models: tumor development
To test potential new drugs against NMIBC in a preclinical
setting, a clinically relevant rodent orthotopic bladder
tumor model is highly desirable. Currently, there are three
diVerent kinds of orthotopic rat bladder tumor models:
chemically induced bladder cancer models [16], the xeno-
graft model (transplantation of human UCC into immuno-
deWcient nude rats) [10] and the syngeneic tumor model
(transplantation of carcinogen-induced bladder cancer in
syngeneic immunocompetent rats) [5].
Given the importance of chemicals in the carcinogenesis
of bladder cancer, organo-speciWc bladder carcinogens
were discovered for rodents. These chemicals provided
readily available reproducible models necessary for
detailed studies of the pathogenesis of bladder cancer [17].
Three chemicals have been reported as being particularly
eVective in causing bladder tumors under the appropriate
conditions: FANFT (N-[4-(5-nitro-2-furyl)-2-thiaz-
olyl]formamide), OH-BBN (N-butyl-N-(4-hydroxybutyl)-
nitrosamine) and MNU (N-methyl-N-nitrosurea) [18, 19].
However, the use of chemicals to induce tumors in the rat
bladder is time-consuming (several months) and there is a
high amount of squamous diVerentiation. Furthermore,
reproducibility is hampered by the variation in time to
tumor development. Therefore, these models are less prac-
tical in therapeutic eYcacy studies of novel anti-prolifera-
tive compounds.
Bladder tumor transplantation is a much faster approach
to create a therapeutic in vivo orthotopic UCC model.
Orthotopic xenografts in immunodeWcient nude rats are
useful in order to better approximate human tumor cell
behavior in situ, but are unsuited to test intravesical immu-
notherapy with for example BCG and are not frequently
used.
Xiao et al. [5]described a syngeneic orthotopic rat model
resembling human UCC, with reproducible tumor growth.World J Urol (2009) 27:313–317 315
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The rat bladder UCC cell line AY-27 was established as a
primary bladder tumor in Fischer F344 rats by feeding
FANFT. This rat bladder UCC cell line was transplanted
orthotopically into female Fischer F344 rats. AY-27 UCC
cells were grown in monolayer cell culture and instilled
intravesically as single cell suspensions into bladders that
had been preconditioned with mild acid washing. In 82
animals sacriWced at 16 days, 80/82 (97%) developed UCC,
and in 52/80 (65%) the tumor was non-muscle invasive
(CIS, T1, but no Ta). Histological examination of the tumor
specimens conWrmed the presence of grade II–III UCC.
Immunocytochemistry conWrmed that the tumor model
maintained the features of UCC.
A potential demerit in this frequently used model is the
timing of intravesical therapy after tumor cell inoculation:
in some rats tumors had not formed yet, while other rats
already developed muscle invasive tumors. Therefore,
Hendricksen et al. [20] assessed the growth of UCC in this
model over time, aiming to have a maximum number of
rats with NMIBC at a particular time and thus optimize the
future starting point of experimental intravesical treat-
ment. It was shown that in this model tumors were formed
at 3–5 days and remained non-muscle invasive up to
5 days. From 6 days, tumors progressed to muscle-inva-
sive disease in 40% of the rats. The observed increase in
tumor aggressiveness might be explained by more pas-
sages in vitro.
Another disadvantage of transplantable models is that
tumors prove to be invasive carcinomas (¸T1) from the
start, without any Ta tumors (which is the most common
stage in human NMIBC). This is related to the bladder pre-
conditioning with urothelial abrasion rather than to the
aggressiveness of the AY-27 cell line. It is quite possible
that the basal membrane is disrupted, which causes rapid
invasion of tumor cells into the underlying layers of the
bladder. However, tumor cells instilled into normal (non-
conditioned) bladders did not result in tumor establishment
[5]. DiVerent methods of tumor establishment in orthotopic
models have been described, ranging from intravesical
instillation of tumor cell suspension after chemical urothe-
lial denudation with MNU or the combination of HCl and
KOH leading to multifocal lesions, to mechanical urothelial
lesioning such as cauterization [21]. Intraparietal injection
of tumor cells resulted in intramuscular tumors only [22,
23]. Horiguchi et al. [24], however, reported also promising
success rates without bladder preconditioning. Thus, the
model could possibly be improved by controlling the uro-
thelial abrasion: the lesion should be only superWcial,
aVecting only one or two of the three cell layers of the rat
bladder urothelium. On the other hand, if one assumes that
tumor cell implantation on the urothelium injured during
TURBT is a major cause of bladder cancer recurrence in
humans, bladder preconditioning would resemble the
clinical situation in case the model is used to test immediate
postoperative intravesical treatments.
Orthotopic models: tumor evaluation
For proper determination of treatment response, conWrma-
tion of successful orthotopic tumor implantation before
starting treatment is desirable. Otherwise one has to rely on
former experiments and conjecture stage and tumor take.
Since there is no accurate documentation of the presence or
extent of tumor before therapy in this case, the validity of
any conclusion on the eYcacy of the experimental agents is
diYcult and large experimental groups are needed to reach
enough power. If the autopsy specimen after treatment con-
tained no tumor one could not conclude whether complete
tumor regression was caused by therapy or whether tumor
implantation had failed. Therefore, a placebo group should
always be added in treatment eYcacy experiments in case
successful tumor implantation before starting treatment
could not be assessed. In any case, there is the disadvantage
of consuming more animals, either due to larger treatment
groups or to adding a placebo group.
Precise quantiWcation of bladder tumor lesions is also
needed to assess responses to intravesical instillation of
therapeutic agents. Accurate non-invasive in vivo assess-
ment of established tumors in the orthotopic model is diY-
cult, particularly for early stage non-muscle invasive
tumors. Magnetic resonance imaging (MRI) has been
reported for this purpose [25, 26]. However, until now it
could not oVer an accurate diagnosis of small early lesions
(<1 mm in diameter) due to its spatial resolution. Further-
more, it is relatively complicated and has high costs. Intra-
vesical ultrasonography was also reported [27], and
provided a positive-predictive ratio of tumor stage up to
85%, however, without information on tumor location and
appearance. Bioluminescence imaging has the potential to
become a valuable tool for the early detection of tumor
growth, although bioluminescence was only Wrst detectable
on day 4 after tumor cell implantation in recently published
studies [28,  29]. Ultrathin cystoscopy [30] is a reliable
method in diagnosing tumor growth in an orthotopic rat
bladder tumor model, with a speciWcity and sensitivity of
>90% [20]. Unfortunately, in our own experience, cystos-
copy is suboptimal in the follow-up of tumors after intra-
vesical treatment in this model. Most probably the rather
short interval between intravesical instillation and cystos-
copy, necessary because of the fast tumor development,
hampers reliable cystoscopy. This lack of a reliable method
to follow-up tumor development makes it diYcult to study
treatment outcomes without sacriWcing the animals,
because the histological examination of the bladder appears
to remain the golden standard for the determination of
tumor growth.316 World J Urol (2009) 27:313–317
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Potential new orthotopic ACI rat bladder tumor 
(RBT323) model
In the search for the ideal animal bladder cancer model, we
are currently developing a new orthotopic ACI rat bladder
tumor (RBT323) model. The RBT323 tumor is a non-car-
cinogen-induced tumor and arose spontaneously in an ACI
rat. In the past, this RBT323 tumor was used as a subcuta-
neous rat bladder tumor model in our laboratory [31, 32].
Histologically, the RBT323 tumor is a grade 2–3 pure uro-
thelial cell tumor with no squamous cells and the RBT323
cell line closely resembles human non-muscle invasive
UCC both phenotypically and cytogenetically [11].
The rather short treatment window of the frequently used
syngeneic orthotopic AY-27/Fischer F344 rat bladder
tumor model hampers its use in the evaluation of new treat-
ments for NMIBC [5]. Moreover, it was recently shown
that carcinogen-induced rodent bladder tumors have gene
expression proWles more similar to those of human invasive
than non-invasive tumors and thus would be a better exper-
imental model for the former [33]. For these reasons, we
anticipated an orthotopic RBT323 tumor in the ACI rat to
be an appropriate syngeneic model to study the anti-tumor
eVects of possible new treatments.
To accomplish this, a RBT323 rat bladder UCC cell line
was established and transplanted orthotopically into synge-
neic female ACI/SeqHSD rats (Harlan Spraque Inc., India-
napolis, Ind.). RBT323 UCC cells were grown in monolayer
cell culture and instilled into preconditioned (mild acid
washing) rat bladders as single cell suspensions. Tumor
growth was assessed by ultrathin cystoscopy (0,5 mm diam-
eter) and 24 days after instillation of tumor cells all rats were
sacriWced and subjected to necropsy. Cystectomy was per-
formed for histopathological examination. Overall in three
out of the four rats tumor was established. All tumors were
non-muscle invasive (T1a–T1c) except one T2a tumor
(2002 TNM staging system). No metastases were found.
Unfortunately, all tumors were covered with normal urothe-
lium (Fig. 1). Still, initial results of this new orthotopic rat
bladder tumor model are promising, because after 24 days
most of the tumors seem to be non-muscle invasive with a
reasonably long time window for the administration of study
drugs, as a consequence. Further studies are now being per-
formed to look for the reproducibility and longitudinal
behavior of the model. Additionally, a study is performed
without bladder preconditioning, but with optimized other
transplantation conditions, trying to establish Ta tumors.
Conclusion
To enable eYcacy testing of new potential chemotherapeu-
tic or immunotherapeutic agents, an orthotopic syngeneic
non-muscle invasive UCC rat bladder tumor model would
be ideal. However, especially tumor cell implantation
methods and diagnostic procedures for the early detection
of tumor growth, and follow-up monitoring still need to be
reWned.
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